Since several studies have shown that neoplasms harboring RAD50, BRCA and RB1 mutations are susceptible to a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP), patients whose tumors present these mutations might benefit from personalized targeted therapy. The gene discussed is RAD50; the disease is neoplasm.